A federal advisory committee voted Thursday to open up rules on seven peptides, including BPC-157 and TB-500. The vote was tight. It is advisory only. The FDA has given no indication on whether it will follow the advice. The move came after weeks of public hearings. Wellness backers pressed strongly for wider access. RFK Jr. was among them. Critics say these compounds have no real proof of safety or help for most uses. The call could redefine how the agency handles a part of the wellness market that is moving at speed. Market observers are watching to see if the agency adopts the plan. A spokesperson for the agency offered no firm timeline for a response. Critics argue the change would open up access to compounds people say help them. Safety voices warn that looser rules could invite misuse across a fast-moving market. The advisory vote only plants the seed for a shift, and the final decision rests with the regulator.